We're now in the cusp where everything can happen
Post# of 72446
(Total Views: 338)
Posted On: 03/13/2018 6:50:54 PM
We're now in the cusp where everything can happen almost overnight.
Leo has moved us forward literally for peanuts. Maximizing every trial to date to demonstrate worthiness. Prurisol to some may be a wild card. I go by the structure (protocol) of the trial when I say the probability of being great is 60%+, being marketable as a competitor is even higher imo.
So we stayed on the otc. A couple hiccups here and there over the years that Leo could have shown better restraint, especially on the up-listing, but I think the company has done well. And is more seasoned to make things count in MUCH bigger ways. Prurisol trial is blinded but the time line is reasonable to see topline data by the end of the month. Maybe some nervous nellies out there that can't handle the anticipation. If you're properly risk based, I say just set your news alerts and take a vacation till news hits. I hope to accumulate a bit more.
So a taste of what I see happening over the next few weeks/couple months...
Prurisol data acceptable to impressive. A status on the oral toxicology for kevetrin. An alignment with big pharma on brilacidin, letter of intent and possibly even a partnership. Upfront payment that covers phase III for OM, with milestones. $30M upfront with milestones.
Up listing, and possibly adding a board member, or two. Independent board members identified.
Getting a timeline nailed down in this sector is next to impossible, but when the wheels start turning, those that have been screwing us, are toast. IPIX is on the right path to make things happen.
Leo has moved us forward literally for peanuts. Maximizing every trial to date to demonstrate worthiness. Prurisol to some may be a wild card. I go by the structure (protocol) of the trial when I say the probability of being great is 60%+, being marketable as a competitor is even higher imo.
So we stayed on the otc. A couple hiccups here and there over the years that Leo could have shown better restraint, especially on the up-listing, but I think the company has done well. And is more seasoned to make things count in MUCH bigger ways. Prurisol trial is blinded but the time line is reasonable to see topline data by the end of the month. Maybe some nervous nellies out there that can't handle the anticipation. If you're properly risk based, I say just set your news alerts and take a vacation till news hits. I hope to accumulate a bit more.
So a taste of what I see happening over the next few weeks/couple months...
Prurisol data acceptable to impressive. A status on the oral toxicology for kevetrin. An alignment with big pharma on brilacidin, letter of intent and possibly even a partnership. Upfront payment that covers phase III for OM, with milestones. $30M upfront with milestones.
Up listing, and possibly adding a board member, or two. Independent board members identified.
Getting a timeline nailed down in this sector is next to impossible, but when the wheels start turning, those that have been screwing us, are toast. IPIX is on the right path to make things happen.
(4)
(0)